Researchers at Verve Therapeutics and collaborating institutions report the results in Nature. Verve, an Eli Lilly subsidiary, funded the work. Most authors are company employees, and several hold Lilly shares or are named on related patent applications.
A brief treatment, a lasting edit
The treatment disables ANGPTL3, a gene encoding a liver-secreted protein that slows the clearance of fats from the blood. Reducing that protein can lower both triglycerides and LDL cholesterol.